USSN: 10/001,563

Attorney Docket No: 3087.00007

-2-

CLAIMS:

1. (Currently amended) A method of augmenting transient protein synthesis in a cell by delivering, directly to the cell, mRNA encoding an <u>eukaryotic translation</u>

initiator initiation factor functionally related to protein synthesis, thereby augmenting

endogenous protein synthesis.

2. (Currently amended) The method according to claim 1, wherein said

delivering step includes intracellularly delivering the mRNA using a method selected

from the group consisting essentially of gene gun delivery, particle acceleration

delivery, and topical devliery delivery.

3. Canceled.

4. (Original) The method according to claim 1, wherein said delivering step

includes particle acceleration of the mRNA to the cell.

- 5. Canceled.
- 6. Canceled.

7. (Currently amended) A method of augmenting transient protein synthesis in

cells in need of increased protein synthesis including the step of directly intracellularly

delivering mRNA encoding a translational regulatory protein functionally related to

protein production an activator of a eukaryotic translation initiator to increase protein

synthesis from endogenous <u>eukaryotic translation initiator</u> mRNA in the cells.

- 3 -

USSN: 10/001,563

Attorney Docket No: 3087.00007

8. (Currently amended) The method according to claim 7, wherein said delivering step further includes delivering mRNA encoding the <u>eukaryotic</u> translation initiator initiator initiator factors to increase protein synthesis.

9-20. Canceled.

21. (Currently amended) A method of augmenting wound healing collagen synthesis and tensile strength of wounds, including the steps of:

directly intracellularly delivering mRNA functionally related to protein production of a eukaryotic translation initiator; and

potentiating an increase in protein synthesis from endogenous cellular mRNA in the wound from the delivered mRNA.

- 22. (Currently amended) The method according to claim 21, wherein said potentiating step includes potentiating the increase in protein synthesis of <u>epidermal</u> growth factors from endogenous cellular mRNA in the wound from the delivered mRNA.
- 23. (Currently amended) The method according to claim 21, wherein said delivering step further includes directly intracellularly delivering mRNA encoding a translational regulatory protein an activator of the eukaryotic translation initiator to increase protein synthesis from endogenous mRNA in the wound.
- 24. (Currently amended) The method according to claim 23 27, wherein said delivering step further includes directly intracellularly delivering mRNA encoding the translation initiation factor 4 is eIF4E to increase protein synthesis from endogenous mRNA in the wound.

USSN: 10/001,563

Attorney Docket No: 3087.00007

25-42. Canceled.

43. (New) The method according to claim 1, wherein the eukaryotic translation initiator is a eukaryotic translation initiation factor 4.

-4-

- 44. (New) The method according to claims 7 or 8, wherein the eukaryotic translation initiator is a eukaryotic translation initiation factor 4.
- 45. (New) The method according to claim 21, wherein the eukaryotic translation initiator is a eukaryotic translation initiation factor 4.